MKI67 and non-small cell lung carcinoma: Compared with the saline group, the PAS group showed significantly lower tumor weights (Figure 7C,D), and IHC staining showed that the positive rate of Ki-67 in tumor cells of the PAS-injected treatment group was significantly lower (Figure 7E,F), further indicating that PAS shows significant antitumor efficacy in human NSCLC in vivo.